Use of Extracellular Vesicles (EV) for Knee Osteoarthrosis

Last updated: April 13, 2025
Sponsor: University of Jordan
Overall Status: Active - Recruiting

Phase

1

Condition

Osteoarthritis

Treatment

Extracellular vesicles

Clinical Study ID

NCT06937528
EVKneeUJCTC
  • Ages 42-75
  • All Genders

Study Summary

Extracellular vesicles (EV) will be injected in patients diagnosed with Knee osteoarthrosis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Severe KOA stage III or IV by Laurance & Kellgren staging as judged byPosterioranterior (PA) Xray of the knee joint.

  • Willing to participate by signing the informed consent

Exclusion

Exclusion Criteria:

  • Sublaxation beyond 20 degrees of the bones of the knee joint

  • Oral anticoagulants or heparin therapy

  • Heart failure or arrhythmia

  • Body Mass Index > 35

  • Uncontrolled Diabetes Mellitus.

  • Evidence of Infectious Diseases.

  • Active infection

  • Malignancy

  • Pregnancy

  • Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia lessthan 3000.

  • Unreliable patients

  • Non-resident in Jordan

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Extracellular vesicles
Phase: 1
Study Start date:
January 01, 2024
Estimated Completion Date:
January 30, 2027

Study Description

50 patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Extracellular vesicles (EV). Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Connect with a study center

  • Cell Therapy Center

    Amman, 00962
    Jordan

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.